Senores Expands Horizons: Acquires Apnar Pharma in ₹910 Million Deal

The deal involves a two-tranche structure: ₹760 million in debt assumption and ₹150 million in cash payment. Apnar Pharma operates USFDA, UK-MHRA, and Health Canada-approved facilities near Vadodara, specializing in generic pharmaceutical formulations. The acquisition is expected to be completed by Q2 FY2027, enhancing Senores’ ability to serve regulated markets and expand its product portfolio.  

Notable updates  
• Senores Pharmaceuticals signs share purchase agreement to acquire Apnar Pharma for ₹910 million enterprise value  
• Transaction structured with ₹760 million debt assumption and ₹150 million cash payment  
• Apnar Pharma’s facilities approved by USFDA, UK-MHRA, and Health Canada  
• Acquisition to be completed in two tranches by Q2 FY2027  
• Strengthens Senores’ presence in regulated markets and expands generics portfolio  

Major takeaway  
The acquisition of Apnar Pharma marks a strategic leap for Senores Pharmaceuticals, bolstering its regulatory-approved manufacturing capacity and reinforcing its ambition to scale globally in the generics space.  

Sources: ScanX News, Economic Times, Senores Pharmaceuticals Media Releases